The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
Open accessAbstract
This study explores whether inflammatory biomarkers act as moderators of clinical response to omega-3 (n-3) fatty acids in subjects with major depressive disorder (MDD). One hundred fifty-five subjects with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) MDD, a baseline 17-item Hamilton Depression Rating Scale (HAM-D-17) score ⩾15 and baseline biomarker data (interleukin (IL)-1ra, IL-6, high-sensitivity C-reactive protein (hs-CRP), leptin and adiponectin) were randomized between 18 May 2006 and 30 June 2011 to 8 weeks of double-blind treatment with eicosapentaenoic acid (EPA)-enriched n-3 1060 mg day−1, docosahexaenoic acid (DHA)-enriched n-3 900 mg day−1 or placebo. Outcomes were determined using mixed model repeated measures analysis for ‘high’ and ‘low’ inflammation groups based on individual and combined biomarkers. Results are presented in terms of standardized treatment effect size (ES) for change in HAM-D-17 from baseline to treatment week 8. Although overall treatment group differences were negligible (ES=−0.13 to +0.04), subjects with any ‘high’ inflammation improved more on EPA than placebo (ES=−0.39) or DHA (ES=−0.60) and less on DHA than placebo (ES=+0.21); furthermore, EPA-placebo separation increased with increasing numbers of markers of high inflammation. Subjects randomized to EPA with ‘high’ IL-1ra or hs-CRP or low adiponectin (‘high’ inflammation) had medium ES decreases in HAM-D-17 scores vs subjects ‘low’ on these biomarkers. Subjects with ‘high’ hs-CRP, IL-6 or leptin were less placebo-responsive than subjects with low levels of these biomarkers (medium to large ES differences). Employing multiple markers of inflammation facilitated identification of a more homogeneous cohort of subjects with MDD responding to EPA vs placebo in our cohort. Studies are needed to replicate and extend this proof-of-concept work.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Self-citationImmune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
A, P. T., A, M. G., & W, A. R. (2003) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200305000-00016 · Cited by 1,024
Rizos, E. C., Ntzani, E. E., Bika, E., Kostapanos, M. S., & Elisaf, M. S. (2012) · JAMA · doi:10.1001/2012.jama.11374 · Cited by 960
Note on an Exact Treatment of Contingency, Goodness of Fit and Other Problems of Significance
Freeman, G. H., & Halton, J. H. (1951) · Biometrika · doi:10.2307/2332323 · Cited by 954 · cited 2×
“Comparisons of response and remission rates at subjects’ last study visit were computed across treatment groups using an extension of Fisher’s Exact Test (37) for the MITT sample and for study completers.”
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Fish consumption and major depression
Hibbeln, J. R. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79168-6 · Cited by 896
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91658-8 · Cited by 690
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1986.tb07607.x · Cited by 603
Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568
Lin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
QUARTAN MALARIAL NEPHROTIC SYNDROME
Hendrickse, R. G., Adeniyi, A., Edington, G. M., Glasgow, E. F., White, R. H. R., & Houba, V. (1972) · The Lancet · doi:10.1016/s0140-6736(72)91373-6 · Cited by 447
Meta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression
Sublette, M. E., Ellis, S. P., Geant, A. L., & Mann, J. J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06634 · Cited by 417
Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease
Yates, C. M., Calder, P. C., & Ed Rainger, G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.010 · Cited by 395
Marangell, L. B., Martinez, J. M., Zboyan, H. A., Kertz, B., Kim, H. F. S., & Puryear, L. J. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.996 · Cited by 380
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch, M. H., & Hannestad, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.100 · Cited by 293
Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J., & Greengard, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104836108 · Cited by 291
Ridker, P. M. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.dec.s253-s259 · Cited by 264
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
Depressive symptoms and metabolic syndrome: is inflammation the underlying link?
Capuron, L., Su, S., Miller, A. H., Bremner, J. D., Goldberg, J., Vogt, G. J., Maisano, C., Jones, L., Murrah, N. V., & Vaccarino, V. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.019 · Cited by 219
Jazayeri, S., Tehrani-Doost, M., Keshavarz, S. A., Hosseini, M., Djazayery, A., Amini, H., Jalali, M., & Peet, M. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701827275 · Cited by 215
Su, K.-P., Lai, H.-C., Yang, H.-T., Su, W.-P., Peng, C.-Y., Chang, J. P.-C., Chang, H.-C., & Pariante, C. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.008 · Cited by 205
Adiponectin in inflammatory and immune-mediated diseases
Fantuzzi, G. (2013) · Cytokine · doi:10.1016/j.cyto.2013.06.317 · Cited by 171
Maes, M., Ruckoanich, P., Chang, Y. S., Mahanonda, N., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.008 · Cited by 169
Ridker, P. M. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00372.x · Cited by 168
Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f3b5f · Cited by 162
Self-citationThe Efficacy of Omega-3 Supplementation for Major Depression
Lespérance, F., Frasure‐Smith, N., St-André, E., Turecki, G., Lespérance, P., & Wisniewski, S. R. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m05966blu · Cited by 149
Lin, P.-Y., Mischoulon, D., Freeman, M. P., Matsuoka, Y., Hibbeln, J., Belmaker, R. H., & Su, K.-P. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.111 · Cited by 145
Self-citationMartins, J. G., Bentsen, H., & Puri, B. K. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.25 · Cited by 145
Gueorguieva, R. V., Mallinckrodt, C., & Krystal, J. H. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.132 · Cited by 125
Long-chain omega 3 fatty acids: Molecular bases of potential antioxidant actions
Giordano, E., & Visioli, F. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.11.002 · Cited by 123
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 112
Evolutionary medicine and chronic inflammatory state—known and new concepts in pathophysiology
Straub, R. H. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0861-8 · Cited by 105
Fenton, J. I., Hord, N. G., Ghosh, S., & Gurzell, E. A. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.09.011 · Cited by 103
Marques-Vidal, P. M., Schmid, R., Bochud, M., Bastardot, F., von Känel, R., Paccaud, F. M., Glaus, J., Preisig, M., Waeber, G., & Vollenweider, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051768 · Cited by 99
Association Between Depression and Inflammation-Differences by Race and Sex: The META-Health Study
Morris, A. A., Zhao, L., Ahmed, Y., Stoyanova, N., Staercke, C. D., Hooper, W. C., Gibbons, G. H., Din‐Dzietham, R., Quyyumi, A. A., & Vaccarino, V. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318222379c · Cited by 95
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
Mischoulon, D., Best-Popescu, C. A., Laposata, M., Merens, W., Murakami, J. L., Wu, S. L., Papakostas, G. I., Dording, C. M., Sonawalla, S. B., Nierenberg, A. A., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.011 · Cited by 94
Self-citationMiller, A. H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.140 · Cited by 78
Role of C Reactive Protein (CRP) in Leptin Resistance
Hribal, M. L., Fiorentino, T. V., & Sesti, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990016 · Cited by 77
Mischoulon, D., Nierenberg, A. A., Schettler, P. J., Kinkead, B. L., Fehling, K., Martinson, M. A., & Rapaport, M. H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m08986 · Cited by 76
Self-citationInflammatory Biomarkers in 70 Depressed Inpatients With and Without the Metabolic Syndrome
Zeugmann, S., Quante, A., Heuser, I., Schwarzer, R., & Anghelescu, I. G. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04767blu · Cited by 57
Rakel, D. P., & Rindfleisch, J. A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2954-0.50092-2 · Cited by 9
Cited by
Inflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844
Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019) · Psychological Medicine · doi:10.1017/s0033291719001454 · Cited by 774
“The literature search yielded 1545 results, out of which 37 studies met the inclusion criteria for meta-analysis (Legros et al., 1985; Penninx et al., 2003; Ladwig et al., 2005; Liukkonen et al., 2006; O’brien et al., 2006; Almeida et al., 2007; Kling et al., 2007; Danese et al., 2008; Nilsson et al., 2008; Cizza et a…”
BackgroundDiet and depression: Exploring the biological mechanisms of action
Marx, W., Lane, M., Hockey, M., Aslam, H., Berk, M., Walder, K., Borsini, A., Firth, J., Pariante, C. M., Berding, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00925-x · Cited by 685
Self-citationFelger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.168 · Cited by 620
Nutritional psychiatry: Towards improving mental health by what you eat
Adan, R. A. H., van der Beek, E. M., Buitelaar, J. K., Cryan, J. F., Hebebrand, J., Higgs, S., Schellekens, H., & Dickson, S. L. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.10.011 · Cited by 454
Metadata
- Authors
- Rapaport, M. H., Nierenberg, A. A., Schettler, P. J., Kinkead, B., Cardoos, A., Walker, R., & Mischoulon, D.
- Venue
- Molecular Psychiatry
- Published
- 2015-03-24
- Volume
- 21
- Issue
- 1
- Pages
- 71-79
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1990532967
- Cited by
- 265
- References
- 50
- FWCI
- 24.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.